Jack Scannell is one of the world’s leading pharmaceutical industry analysts, as well as one of its most visionary. Jack caused a case of global pharmaceutical R&D indigestion when, a decade ago, he identified in a groundbreaking Nature publication that, unlike in the semi-conductor industry, which had seen the doubling of its productivity every 10 years, the exact opposite was true for the biopharmaceutical sector, where productivity had instead halved in each successive decade.Jack Scannell investigates R&D productivity from both an economic and a scientific perspective, with a focus on the fact that the cost of scientific inputs has dropped exponentially, yet, the drug and biotech industries have seen a huge long-term decline in innovative output efficiency. He works as an independent consultant to drug and biotech firms, financial institutions, and the public sector. He was head of Discovery Research at e-Therapeutics, an Oxford-based biotechnology firm. He’s also worked for the Boston Consulting Group.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related